On 6 May 2024, NYSE-listed ADC Therapeutics SA, a commercial-stage biotechnology company based in Lausanne, Switzerland, announced that it had agreed to sell, by way of an underwritten offering, 13.4 million of its common shares as well as pre-funded warrants to purchase 8.1 million common shares to raise aggregate gross proceeds of approx. USD 105 million.
CapLaw Themes
- FinSA (FIDLEG) (32)
- FinIA (FINIG) (11)
- Insurance (8)
- Securities (92)
- Regulatory (128)
- Takeover (19)
- Derivatives (7)
- News, Deals & Cases (450)
- Events (149)
- Other Areas (8)
CapLaw PDF Archive
Discover more articles
We provide up-to-date information on legal and regulatory developments regarding the capital markets, publish concise articles on developments in the Swiss and international financial markets, and announce recent deals and forthcoming events.